GB9810193D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
GB9810193D0
GB9810193D0 GBGB9810193.4A GB9810193A GB9810193D0 GB 9810193 D0 GB9810193 D0 GB 9810193D0 GB 9810193 A GB9810193 A GB 9810193A GB 9810193 D0 GB9810193 D0 GB 9810193D0
Authority
GB
United Kingdom
Prior art keywords
novel compounds
novel
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9810193.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Priority to GBGB9810193.4A priority Critical patent/GB9810193D0/en
Publication of GB9810193D0 publication Critical patent/GB9810193D0/en
Priority to CA002328061A priority patent/CA2328061A1/en
Priority to EP99950345A priority patent/EP1086127A1/en
Priority to PCT/EP1999/003262 priority patent/WO1999058562A2/en
Priority to AU42601/99A priority patent/AU4260199A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
GBGB9810193.4A 1998-05-12 1998-05-12 Novel compounds Ceased GB9810193D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GBGB9810193.4A GB9810193D0 (en) 1998-05-12 1998-05-12 Novel compounds
CA002328061A CA2328061A1 (en) 1998-05-12 1999-05-10 Novel compounds
EP99950345A EP1086127A1 (en) 1998-05-12 1999-05-10 Novel compounds
PCT/EP1999/003262 WO1999058562A2 (en) 1998-05-12 1999-05-10 Novel compounds
AU42601/99A AU4260199A (en) 1998-05-12 1999-05-10 Novel compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9810193.4A GB9810193D0 (en) 1998-05-12 1998-05-12 Novel compounds

Publications (1)

Publication Number Publication Date
GB9810193D0 true GB9810193D0 (en) 1998-07-08

Family

ID=10831938

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9810193.4A Ceased GB9810193D0 (en) 1998-05-12 1998-05-12 Novel compounds

Country Status (5)

Country Link
EP (1) EP1086127A1 (en)
AU (1) AU4260199A (en)
CA (1) CA2328061A1 (en)
GB (1) GB9810193D0 (en)
WO (1) WO1999058562A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
JP2008504292A (en) 2004-06-24 2008-02-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Immune enhancement compounds
JP2009511636A (en) 2005-10-18 2009-03-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Mucosal and systemic immunity with alphavirus replicon particles
JP5215865B2 (en) 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド Norovirus and sapovirus antigens
US20090317421A1 (en) 2006-01-18 2009-12-24 Dominique Missiakas Compositions and methods related to staphylococcal bacterium proteins
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
RU2471497C2 (en) 2007-09-12 2013-01-10 Новартис Аг Mutant antigens gas57 and gas57 antibodies
WO2009081274A2 (en) 2007-12-21 2009-07-02 Novartis Ag Mutant forms of streptolysin o
US8466167B2 (en) 2008-03-03 2013-06-18 Irm Llc Compounds and compositions as TLR activity modulators
CA2749367A1 (en) 2009-01-12 2010-07-15 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria
CA2765112A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
EP2443250B8 (en) 2009-06-16 2016-09-21 GlaxoSmithKline Biologicals SA High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays
ES2443952T3 (en) 2009-09-02 2014-02-21 Novartis Ag Immunogenic compositions that include modulators of TLR activity
JO3257B1 (en) 2009-09-02 2018-09-16 Novartis Ag Compounds and compositions as tlr activity modulators
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
US9408907B2 (en) 2009-12-15 2016-08-09 Glaxosmithkline Biologicals Sa Homogenous suspension of immunopotentiating compounds and uses thereof
EP2549990A1 (en) 2010-03-23 2013-01-30 Irm Llc Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
CN102933267B (en) 2010-05-28 2015-05-27 泰特里斯在线公司 Interactive hybrid asynchronous computer game infrastructure
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
CN105188747A (en) 2013-02-01 2015-12-23 葛兰素史密斯克莱生物公司 Intradermal delivery of immunological compositions comprising TOLL-like receptor agonists
US11458151B2 (en) 2018-02-12 2022-10-04 Inimmune Corporation Toll-like receptor ligands
CA3198924A1 (en) 2020-11-04 2022-05-12 Eligo Bioscience Phage-derived particles for in situ delivery of dna payload into c. acnes population

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712118A (en) * 1993-09-29 1998-01-27 Research Foundation Of State University Of New York Vaccine for branhamella catarrhalis
US5607846A (en) * 1994-05-17 1997-03-04 Research Foundation Of State University Of New York Vaccine for moraxella catarrhalis
US7341727B1 (en) * 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
US6004562A (en) * 1996-08-16 1999-12-21 The Research Foundation Of The State University Of New York Outer membrane protein B1 of Moraxella catarrhalis

Also Published As

Publication number Publication date
WO1999058562A3 (en) 2001-05-17
WO1999058562A2 (en) 1999-11-18
EP1086127A1 (en) 2001-03-28
AU4260199A (en) 1999-11-29
CA2328061A1 (en) 1999-11-18

Similar Documents

Publication Publication Date Title
GB9803411D0 (en) Novel compounds
GB9810193D0 (en) Novel compounds
GB9802661D0 (en) Novel compounds
GB9800337D0 (en) Novel compounds
GB9800289D0 (en) Novel compounds
GB9800317D0 (en) Novel compounds
GB9800324D0 (en) Novel compounds
GB9801630D0 (en) Novel compounds
GB9801633D0 (en) Novel compounds
GB9801634D0 (en) Novel compounds
GB9801635D0 (en) Novel compounds
GB9801643D0 (en) Novel compounds
GB9802658D0 (en) Novel compounds
GB9801882D0 (en) Novel compounds
GB9802387D0 (en) Novel compounds
GB9819278D0 (en) Novel compounds
GB9803566D0 (en) Novel compounds
GB9803428D0 (en) Novel compounds
GB9803306D0 (en) Novel compounds
GB9803290D0 (en) Novel compounds
GB9803289D0 (en) Novel compounds
GB9803287D0 (en) Novel compounds
GB9803246D0 (en) Novel Compounds
GB9803242D0 (en) Novel compounds
GB9803194D0 (en) Novel compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)